Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Search for other papers by John B McIntyre in
Google Scholar
PubMed
Search for other papers by Adrian Box in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Search for other papers by Dean Ruether in
Google Scholar
PubMed
Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
mutation-positive medullary thyroid cancer (MTC) or RET gene fusion-positive thyroid cancer. The early approval of these drugs was based on phase 1/2 data ( 1 , 2 , 3 , 4 , 5 ). Patients with thyroid cancer were one of the larger patient groups in the
Search for other papers by Thea Riis in
Google Scholar
PubMed
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
Search for other papers by Thomas Heiberg Brix in
Google Scholar
PubMed
Search for other papers by Lars Folkestad in
Google Scholar
PubMed
Introduction Cancer is the second most common cause of death worldwide and imposes a burden both individually and to the health care systems ( 1 ). It has been suggested that four out of ten cancer cases are preventable ( 2 ). Therefore
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Alexandra Stephenson in
Google Scholar
PubMed
Search for other papers by Shideh Mirhadi in
Google Scholar
PubMed
Search for other papers by Konrad Patyra in
Google Scholar
PubMed
Search for other papers by Michael F Moran in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Department of Pediatrics, Turku University Hospital, Turku, Finland
Search for other papers by Jukka Kero in
Google Scholar
PubMed
Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Department of Medicine, Cumming School of Medicine, University of Calgary, Heritage Medical Research Building, Calgary, Alberta, Canada
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
/hormone synthesis ( 4 , 5 , 6 , 7 , 8 , 9 ). At variance with most other thyroid nodules, current textbooks and guidelines assess HTN as a low cancer risk with no further malignancy evaluation recommended ( 10 ). To understand the role of TSHR signaling in
Search for other papers by Lan Wu in
Google Scholar
PubMed
Search for other papers by Salvatore Vaccarella in
Google Scholar
PubMed
Search for other papers by Chen-Yang Feng in
Google Scholar
PubMed
Search for other papers by Luigino Dal Maso in
Google Scholar
PubMed
Search for other papers by Yu Chen in
Google Scholar
PubMed
Search for other papers by Wei-Wei Liu in
Google Scholar
PubMed
Search for other papers by Miao-Bian Liang in
Google Scholar
PubMed
Search for other papers by Zike Zhang in
Google Scholar
PubMed
Search for other papers by Jun Yang in
Google Scholar
PubMed
Search for other papers by Su-Mei Cao in
Google Scholar
PubMed
Search for other papers by Mengmeng Li in
Google Scholar
PubMed
Introduction Thyroid cancer is the most common cancer in the endocrine system, and its incidence rates have increased rapidly worldwide over the past decades, with relatively stable or declining mortality rates ( 1 , 2 ). The diverging gap
Search for other papers by Stacey A. Fedewa in
Google Scholar
PubMed
Search for other papers by Ahmedin Jemal in
Google Scholar
PubMed
Search for other papers by Amy Y. Chen in
Google Scholar
PubMed
Introduction Each year, 64,300 men and women are diagnosed with thyroid cancer [ 1 ]. Approximately 90% of thyroid cancers are differentiated tumors comprised of papillary and follicular tumors that are commonly diagnosed at an early stage and
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by Annick Van den Bruel in
Google Scholar
PubMed
Search for other papers by Gilles Macq in
Google Scholar
PubMed
Search for other papers by Nathalie Elaut in
Google Scholar
PubMed
Search for other papers by Harlinde De Schutter in
Google Scholar
PubMed
Introduction In Belgium, higher thyroid cancer incidence – most pronounced for microcancers (T1a) – is present in the Southern region, Wallonia, compared to the Northern region, Flanders. In a pioneer national population
Search for other papers by Janice Ser Huey Tan in
Google Scholar
PubMed
Search for other papers by Timothy Kwang Yong Tay in
Google Scholar
PubMed
Search for other papers by Enya Hui Wen Ong in
Google Scholar
PubMed
Search for other papers by Michael Fehlings in
Google Scholar
PubMed
Search for other papers by Daniel Shao-Weng Tan in
Google Scholar
PubMed
Search for other papers by Nadiah Binte Sukma in
Google Scholar
PubMed
Search for other papers by Eileen Xueqin Chen in
Google Scholar
PubMed
Search for other papers by Jen-Hwei Sng in
Google Scholar
PubMed
Search for other papers by Connie Siew Poh Yip in
Google Scholar
PubMed
Search for other papers by Kok Hing Lim in
Google Scholar
PubMed
Search for other papers by Darren Wan-Teck Lim in
Google Scholar
PubMed
Search for other papers by Narayanan Gopalakrishna Iyer in
Google Scholar
PubMed
Search for other papers by Jacqueline Siok Gek Hwang in
Google Scholar
PubMed
Search for other papers by Melvin Lee Kiang Chua in
Google Scholar
PubMed
Search for other papers by Mei-Kim Ang in
Google Scholar
PubMed
Introduction Anaplastic thyroid cancers (ATCs) are rare aggressive tumours, comprising only 1–2% of all thyroid cancers worldwide, and are typically associated with high mortality rates and a median overall survival (OS) of 5–12 months ( 1
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Constance Xhaard in
Google Scholar
PubMed
Search for other papers by Juan J. Lence-Anta in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Yan Ren in
Google Scholar
PubMed
Rhône-Alpes Thyroid Cancer Registry, Cancer Research Center of Lyon (UMR INSERM 1052, CNRS 5286), RTH Laennec Faculty of Medicine, University of Lyon, Lyon
Search for other papers by Françoise Borson-Chazot in
Google Scholar
PubMed
Search for other papers by Geneviève Sassolas in
Google Scholar
PubMed
Search for other papers by Claire Schvartz in
Google Scholar
PubMed
Search for other papers by Marc Colonna in
Google Scholar
PubMed
French National Registry of Childhood Solid Tumours, CHU, Nancy
Search for other papers by Brigitte Lacour in
Google Scholar
PubMed
Search for other papers by Arlette Danzon in
Google Scholar
PubMed
Search for other papers by Michel Velten in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Enora Clero in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Stéphane Maillard in
Google Scholar
PubMed
Search for other papers by Emilie Marrer in
Google Scholar
PubMed
Search for other papers by Laurent Bailly in
Google Scholar
PubMed
Search for other papers by Eugènia Mariné Barjoan in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Jacques Orgiazzi in
Google Scholar
PubMed
Université Paris-Saclay, Villejuif, France
Search for other papers by Elisabeth Adjadj in
Google Scholar
PubMed
Search for other papers by Celia M. Pereda in
Google Scholar
PubMed
Search for other papers by Silvia Turcios in
Google Scholar
PubMed
Search for other papers by Milagros Velasco in
Google Scholar
PubMed
Search for other papers by Mae Chappe in
Google Scholar
PubMed
Search for other papers by Idalmis Infante in
Google Scholar
PubMed
Search for other papers by Marlene Bustillo in
Google Scholar
PubMed
Search for other papers by Anabel García in
Google Scholar
PubMed
Search for other papers by Sirced Salazar in
Google Scholar
PubMed
Search for other papers by Regla Rodriguez in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Mohamed Amine Benadjaoud in
Google Scholar
PubMed
Search for other papers by Rosa M. Ortiz in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Carole Rubino in
Google Scholar
PubMed
Institut Gustave Roussy, Villejuif, France
Université Paris-Saclay, Villejuif, France
Search for other papers by Florent de Vathaire in
Google Scholar
PubMed
Introduction Over the last few decades, the differentiated thyroid cancer (DTC) incidence has grown rapidly in many countries [ 1 ]. The study of DTC risk factors is therefore of great importance to understand this observed increase in
Search for other papers by Aamna Hassan in
Google Scholar
PubMed
Search for other papers by Saima Riaz in
Google Scholar
PubMed
Search for other papers by Humayun Bashir in
Google Scholar
PubMed
Search for other papers by M. Khalid Nawaz in
Google Scholar
PubMed
Search for other papers by Raza Hussain in
Google Scholar
PubMed
Introduction Differentiated thyroid cancer (DTC) is typically indolent if treated early and appropriately. A small subset of more aggressive disease progresses to radioiodine resistance. Based on the American Thyroid Association (ATA) risk of
Search for other papers by Patrick W. Owens in
Google Scholar
PubMed
Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Search for other papers by Terri P. McVeigh in
Google Scholar
PubMed
Search for other papers by Eoin J. Fahey in
Google Scholar
PubMed
Search for other papers by Marcia Bell in
Google Scholar
PubMed
Search for other papers by Denis S. Quill in
Google Scholar
PubMed
Search for other papers by Michael J. Kerin in
Google Scholar
PubMed
Search for other papers by Aoife J. Lowery in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) is the most common endocrine malignancy, accounting for 1% of all cancers, with an incidence of 162 cases per year in Ireland [ 1 ]. The National Cancer Registry Ireland reports increasing incidence of TC from